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Abstract
Background: The nitric oxide (NO) pathway is involved in asthma, and eosinophils participate in the regulation of the NO
pool in pulmonary tissues. We investigated associations between single nucleotide polymorphisms (SNPs) of NO synthase
genes (NOS) and biological NO-related phenotypes measured in two compartments (exhaled breath condensate and
plasma) and blood eosinophil counts.
Methodology: SNPs (N=121) belonging to NOS1, NOS2 and NOS3 genes were genotyped in 1277 adults from the French
Epidemiological study on the Genetics and Environment of Asthma (EGEA). Association analyses were conducted on four
quantitative phenotypes: the exhaled fraction of NO (FENO), plasma and exhaled breath condensate (EBC) nitrite-nitrate
levels (NO2–NO3) and blood eosinophils in asthmatics and non-asthmatics separately. Genetic heterogeneity of these
phenotypes between asthmatics and non-asthmatics was also investigated.
Principal Findings: In non-asthmatics, after correction for multiple comparisons, we found significant associations of FeNO
levels with three SNPs in NOS3 and NOS2 (P#0.002), and of EBC NO2–NO3 level with NOS2 (P=0.002). In asthmatics, a single
significant association was detected between FENO levels and one SNP in NOS3 (P=0.004). Moreover, there was significant
heterogeneity of NOS3 SNP effect on FeNO between asthmatics and non-asthmatics (P=0.0002 to 0.005). No significant
association was found between any SNP and NO2–NO3 plasma levels or blood eosinophil counts.
Conclusions: Variants in NO synthase genes influence FeNO and EBC NO2–NO3 levels in adults. These genetic determinants
differ according to asthma status. Significant associations were only detected for exhaled phenotypes, highlighting the
critical relevance to have access to specific phenotypes measured in relevant biological fluid.
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Introduction
The endogenous nitric oxide (NO) plays a key role in
physiological regulation of airway functions and is implicated in
airway diseases such as asthma [1,2]. In biological fluids, the half-
life of NO is extremely short due to its rapid oxidation to nitrite
(NO2-) and nitrate (NO3-) [3]. NO2- and NO3- should now be
viewed as storage pools for NO-like bioactivity, thereby comple-
menting the NO synthase (NOS)-dependent pathway [3].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36672The measure of exhaled fraction of NO (FENO) is considered as
a marker for eosinophilic inflammation in asthma, and can be used
together with sputum eosinophil counts to titrate anti-inflamma-
tory treatment in asthmatic patients [4–6]. There are in vitro
evidences that human blood eosinophils produce NO and
participate in the regulation of the NO pool in pulmonary tissues
[7,8]. The NO modulates the Th1/Th2 balance by favoring Th2
response and IL-5 production and thus recruiting eosinophils into
the airways [7,8]. Moreover, inactivation of the inducible Nitric
Oxide Synthase (iNOS), one of the key enzymes in the formation
of NO, decreases the eosinophil count in bronchial alveolar lavage
and in blood [9].
Nitric oxide is endogenously produced by three nitric oxide
synthase isoforms (NOSs, EC 1.14.13.39): a neuronal isoform
(nNOS or NOS-1), an inducible isoform (iNOS or NOS-2) and a
vascular endothelial isoform (eNOS or NOS-3) [10]. These
proteins are encoded by three distinct genes: NOS1, NOS2
(previously NOS2A) and NOS3 located on chromosome 12, 17
and 7 respectively. The three NOS isoforms are expressed by
human airway epithelial cells [11]. It is admitted that NOS-1 and
NOS-3 control low levels of NO to perform physiological
functions whereas NOS-2 shows increased expression during
inflammation and is expressed predominantly in T cells, macro-
phages and epithelial cells [12]. Further, NOS-2 activity is the
major determinant of nitric oxide levels in exhaled breath [13].
Despite the biological evidence of a physiological link between
eosinophils and NO, only one study has investigated associations
between variants in NOS genes and both eosinophils and NO [14].
The authors reported associations between allele 3 of the intron 4
(GT)n repeat belonging to NOS2 and both percentage of blood
eosinophils and serum nitric oxide levels in 230 families
ascertained through asthma. However, only four variants in
NOS2 gene were investigated in that study, and the modifying
effect of asthma was not studied.
Table 1. Characteristics of non-asthmatics and asthmatic subjects.
Non-asthmatic Subjects N=783
Asthmatic
subjects N=494
Age, year, mean 6 SD 46.6615.8 39.8616.4
Sex, women, % 53.9 49.0
Smoking habits:
Never smokers, % 51.1 49.0
Ex-smokers, % 27.8 25.5
Current smokers, % 21.1 25.5
Asthma
FEV1 % predicted, mean 6 SD 106.7616.5 95.4619.0
Methacholine test, PD20#4 mg,* n (%) 493 (27.4) 285 (70.5)
Inhaled corticosteroids, last 3 months, % 0.0 17.6
Inhaled corticosteroids, last 12 months, % 3.5 48.4
Age at onset of asthma, n: / 437
#4 yrs, % NA 30.4
]4216] yrs, % NA 34.3
.16 yrs, % NA 35.2
Asthma severity according to GINA 2006 guidelines, n: 469
Intermittent, % NA 55.4
Mild persistent, % NA 3.8
Moderate persistent, % NA 12.3
Severe persistent, % NA 28.4
SPT+ and allergic rhinitis
SPT+#, % 39.1 80.6
SPTQ, median [Q1–Q3
$] 0 [0–1] 2 [1–4]
IgE, IU/ml, median [Q1–Q3] 43.3 [16.5–122] 162 [64.7–377]
Allergic rhinitis, % 22.1 60.1
Biological phenotypes, median [Q1-Q3]
Eosinophils/mm
3 130 [100–200] 200 [140–320]
FeNO, ppb 14.9 [9.05–19.5] 18.0 [11.9–28.9]
Plasma NO2–NO3, mM 35.7 [24.8–51.6] 36.5 [25.9–50.1]
EBC NO2–NO3, mmol/mg 2.01 [0.92–3.78] 1.90 [0.85–4.06]
#Skin Prick Test positivity (SPT+) was defined by a mean wheal diameter$3 mm than the negative control for at least one of 11 aeroallergens. SPTQ: number of positive
test.
IgE: immunoglobulin E, NA: not available. *Not performed if FEV1,80% predicted.
$Q1–Q3=first and third quartile.
doi:10.1371/journal.pone.0036672.t001
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associations between 121 Single Nucleotide Polymorphisms (SNPs)
of NOS1, NOS2 and NOS3 genes with 1) the three biological
phenotypes of the nitrate-nitrite-NO pathway [3]: FENO levels,
total nitrite-nitrate levels measured both in plasma and in exhaled
breath condensate, and 2) blood eosinophil counts, in 1277
asthmatic and non-asthmatic adults from the French Epidemio-
logical study on the Genetics and Environment of Asthma
(EGEA). Moreover, we tested for heterogeneity of genetic variant
effect on these four phenotypes between non-asthmatic and
asthmatic subjects. In this study, we had the unique possibility to
compare the associations between NOS variants and total nitrite-
nitrate levels measured in two compartments: plasma and exhaled
breath condensate.
Results
Characteristics of non-asthmatic and asthmatic subjects are
shown in Table 1. Subjects with current asthma were younger
than non-asthmatic subjects, had significantly lower % predicted
FEV1, more often hyperresponsiveness, and were more often
atopic (all P,0.0001). Eosinophil counts (EOS) and FENO levels
were significantly higher in asthmatic subjects than in non-
asthmatic subjects (P,0.0001). No significant difference was
observed for plasma or EBC NO2–NO3 levels between both
groups.
Table 2 presents pair-wise associations between the three
biological phenotypes of nitrite-nitrate-NO pathway and eosino-
phil counts. There was no association between plasma and EBC
NO2–NO3 levels both in non-asthmatic and asthmatic subjects.
FENO levels were positively associated with blood EOS counts both
in non-asthmatic and asthmatic subjects. In non-asthmatic
subjects, plasma NO2–NO3 was positively associated with blood
EOS counts, and both plasma and EBC NO2–NO3 levels were
positively associated with FENO levels. In asthmatic subjects, EBC
NO2–NO3 was positively associated with EOS counts. Among
asthmatic subjects, associations remained similar when analyses
were restricted to those who did not receive inhaled corticosteroids
(ICS) in the last three months.
Single marker analysis
In non-asthmatic subjects, two SNPs in NOS3 (rs2853796 and
rs1549758, P#0.0009, LD: D9=1 and r
2=0.08) and one SNP in
NOS2 (rs6505510, P=0.002) were significantly associated with
FENO levels after adjustment for multiple comparisons (Table 3
and Table S2). The CC genotype of rs6505510, C and T alleles of
rs1549758 and rs2853796 respectively were associated with
increased levels of FENO. We observed significant associations
between EBC NO2–NO3 levels and one SNP belonging to NOS2
(rs4795067, P=0.002), subjects with at least one copy of G allele
having higher NO2–NO3 levels (Table 3 and Table S3). No
significant association was observed between any SNP and plasma
or blood phenotypes (NO2–NO3 plasma levels and EOS count
(Tables S4 and S5).
In asthmatic subjects, after adjustment for multiple compari-
sons, a single significant association was detected between FENO
levels and one SNP in NOS3 (rs743507, P=0.004), the C allele of
rs743507 being associated with increased levels of FENO (Table 3
and Table S2). We did not observed any association signal
between SNPs and the three other phenotypes under study that
reached the critical p-value thresholds taking into account multiple
testing.
There was significant heterogeneity of NOS3 SNP effect on
FeNO levels according to asthma status (Table S2), with opposite
allele effects between subjects with and without asthma. The most
significant interaction was observed for rs743507 (PInt=0.0002).
Multi-marker analysis
In non-asthmatic subjects, stepwise regression analyses showed
independent effect of two NOS2 SNPs: rs12601458 and rs6505510
(P=0.01 and P=0.003 respectively, with D9=0.38 and r
2=0.02)
and a single NOS3 SNP (rs2853796, p=0.0007) on FENO levels
(Table 4).
Multiple regressions performed in non-asthmatic subjects
showed independent effects of two NOS2 SNPs: rs4795067 and
rs4796190 (P=0.002 and P=0.01 respectively, with D9=0.09
and r
2=0.002) on EBC NO2–NO3 levels (Table 4).
Among asthmatics, a single NOS3 SNP (rs743507) was
associated with FeNO levels with similar results in the multi-
marker analysis as compared to the single marker analysis
(n=189, estimate=0.0745, 95%CI (0.017,0.132), P=0.01).
Discussion
The present study investigated for the first time simultaneously
the associations between the three genes of the NOS family and
biological phenotypes in the nitrate-nitrite-NO pathway measured
in plasma and in exhaled breath condensate (EBC), and blood
eosinophil count. The compartmentalized formation of NO
(plasma and exhaled breath condensate) and the modifying effect
of asthma status on these associations were also investigated.
Regardless of asthma status, significant associations were found
only for exhaled biological phenotypes (FeNO and EBC NO2–NO3
levels). The association of FeNO with NOS3 variants clearly differed
between asthmatics and non-asthmatics.
In the present study, we only observed significant associations
between NOS polymorphisms and the two exhaled phenotypes
(FeNO and EBC NO2–NO3) whereas biological phenotypes under
study, especially NO2–NO3, were measured both in blood and in
exhaled breath condensate. Whatever asthma status, FENO levels
were associated with genetic variants belonging to NOS3. In non-
asthmatic subjects, both FeNO and EBC NO2–NO3 levels were
associated with genetic variants belonging to NOS2 which encodes
NOS-2, the major enzyme producing NO in exhaled breath [13].
No association was detected for plasma NO2–NO3 levels neither
in non-asthmatic nor in asthmatic subjects. Moreover, plasma
NO2–NO3 levels were not correlated to EBC NO2–NO3 levels in
our study. Production of NO2–NO3 in EBC differs from that in
plasma due to their compartmentalization: ionized nitrate and
nitrite (not volatile) may arise in EBC from NO after reaction with
oxygen [15] or from activated immune cells presents in the lining
of the lungs [16]. Opposite to EBC, the production of NO2–NO3
in plasma is more complex where it derives from endogenous as
well as dietary sources [17]. A NOS independent formation of NO
also occurs in mammal blood and tissues through several
enzymatic and nonenzymatic routes [18]. Overall, the specificities
of NO metabolism in plasma and EBC may partly explain our
results. They are consistent with the hypotheses of Villanueva and
Giulvini [19], for whom such compartmentalized production of
NO better explain its different functions and roles in pathophys-
iology, and highlight the interest to carefully choose the fluid in
which a biological phenotype should be measured to study their
association with genetic factors.
Inhaled corticosteroid (ICS) can modify FeNO levels, but no
association between ICS and NO2–NO3 in EBC has yet been
evidenced [20,21]. To avoid any masking effect of ICS on the
association between genetic determinants and FeNO levels, we
restricted our analyses in subjects with asthma to those who did
NOS Genes, Exhaled NO-Related Phenotypes, Asthma
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measurement of exhaled NO levels. A relatively small proportion
(17%) of subjects with current asthma did take ICS in that period
and such ICS use did not significantly modify the association
between FeNO and asthma (data not shown). The significant
associations detected when restricting the analysis to subjects with
asthma who did not receive ICS in the last three months before the
FENO measurement were stronger.
To date, very few studies have investigated associations between
FENO level and polymorphisms in the three NOS genes in adults
with asthma [22,23,24], or simultaneously considered blood
eosinophil count and serum nitric oxide level [14]. Three of these
studies have studied very few polymorphisms whithin each gene
(one to four variants) and no study has sought for association with
nitrite-nitrate levels. The first two studies conducted in less than
100 asthmatic subjects, reported association between FENO levels
and genetic variants in NOS3 (G894T) [22] and NOS1 (AAT
repeats in intron 13 (formely intron 20) [23]). One study
investigated four microsatellites belonging to NOS2 in families
with asthma and reported association between allele 3 of the
intron 4 (GT)n repeat and both percentage of blood eosinophils
and serum nitric oxide level [14]. In the present study, a single
association between FENO levels and NOS3 variants was detected
in asthmatics (rs743507, P=0.004 with PInt=0.0002). Methodo-
logical differences as correction for multiple comparisons and
others related to the population studied (sample size, asthma
definition, measurements of biological phenotypes) may partly
explain the discrepancy between all these results. Several
hypotheses may explain that overall we found a reduced number
of significant signals among subjects with asthma than in those
without asthma: the interplay of complex mechanisms including
genetic and/or environmental factors and their interactions, some
Table 2. Pair-wise association of eosinophil count and NO-related phenotypes in non-asthmatic and asthmatic subjects.
Eosinophils/mm
3* FeNO, ppb# Plasma NO2–NO3, mM*
n Estimate SD p-value n Estimate SD p-value n Estimate SD p-value
Non-asthmatic subjects
EBC NO2-NO3,mol/mg* 534 20.03 0.07 0.67 262 0.27 0.11 0.02 523 0.002 0.08 0.97
Plasma NO2–NO3, mM* 661 0.11 0.04 0.001 327 0.13 0.05 0.008
FeNO, ppb# 364 0.20 0.04 ,0.0001
Asthmatic subjects
EBC NO2-NO3,mol/mg* 346 0.21 0.1 0.03 202 0.14 0.12 0.24 336 0.15 0.12 0.22
Plasma NO2–NO3, mM* 418 0.03 0.04 0.40 240 0.07 0.05 0.12
FeNO, ppb# 257 0.32 0.06 ,0.0001
Estimates are adjusted for *age and sex, or
#age, sex, height, smoking and centre (GEE regression methods).
doi:10.1371/journal.pone.0036672.t002
Table 3. Associations between SNPs belonging to NOS2 and NOS3 and two quantitative phenotypes measured in the exhaled
breath condensate (FeNO level and NO2–NO3 level) in non-asthmatic and asthmatic subjects–Single marker analysis.
Exhaled phenotypes
FeNO, ppb NO2-NO3, mmol/mg
Chromosome Gene
Genotyping
method Marker
Position
(bp)
Major
allele*
Minor
allele MAF
{ beta 95% CI
# P beta 95% CI
# P
Non-asthmatic subjects
17 NOS2{ 610K rs4795067 23130802 A G 0.35 20.04 20.10;
0.03
0.26 0.13 0.04;
0.22
0.002
610K rs6505510 23203917 A C 0.40 0.10 0.04;
0.17
0.002 0.08 20.01;
0.17
0.07
7 NOS3{ Taqman rs1549758 150326659 C T 0.35 20.06 20.10;
20.02
0.0009 0.003 20.06;
0.06
0.92
Taqman rs2853796 150334848 G T 0.48 0.06 0.02;
0.09
0.0007 20.02 20.08;
0.04
0.46
Asthmatic subjects
7 NOS3{ 610K rs743507 150338421 T C 0.27 0.08 0.03;
0.14
0.004 0.02 20.07;
0.11
0.65
In bold P-values surviving the adjustment (P#0.0024 or P#0.01 for NOS2 and NOS3 respectively).
*Major allele was consider as baseline allele
{MAF: Minor allele frequency
#CI: confidence interval
{Analyses were conducted under an additive genetic model for NOS3 SNPs and under recessive or dominant genetic models for NOS2 SNPs and FeNO and EBC NO2–
NO3 levels respectively.
doi:10.1371/journal.pone.0036672.t003
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which included more than 50% with intermittent asthma, or a lack
of power due to the small sample size of subjects with asthma.
Indeed the lack of internal replication within our study between
the two groups might also be due to chance findings among those
without asthma. Such a possibility was addressed within our
analysis by careful consideration of multiple testing. Further,
recent results in an independent population support our findings
and confirm significant heterogeneity between subjects with and
without asthma [24]. In that study conducted in 1700 Swedish
adults, Dahgam et al. [24] reported significant association between
rs7830 belonging to NOS3 and FeNO levels only in subjects with
asthma. Interestingly, this SNP is in linkage disequilibrium with
rs743507 (D9=1, r
2=0.2) for which we detected significant
association with FeNO level in subjects with asthma only, and the
T risk allele of rs7830 is associated with the T risk allele of
rs743507. The region of strong LD where these two SNPs are
located is common to two genes NOS3 and ATG9B (ATG9
autophagy related 9 homolog B) which functionally interact:
ATG9B gene functions as the antisense to and in the posttran-
scriptional regulation of endothelial nitric oxide synthase 3.
Our results extend observations on the genetic determinants of
FeNO levels conducted in children, more often studied than adults
until now. In children without asthma [25], significant associations
have been evidenced between FeNO levels and genetic variants of
NOS2 promoter region (including rs1889022 and rs10853181, two
SNPs in LD with rs6505510 (D9=1, r
2=0.4) associated with
FeNO levels in adults without asthma in our study). The C allele of
rs6505510 is associated with G alleles of both rs1889022 and
rs10853181 on the same haplotype, and Salam et al. [25] reported
that haplotypes carrying both G alleles (Major alleles) of
rs1889022 and rs10853181 were associated with higher FeNO
levels than non-carrying, consistent with our observations on the C
allele of rs6505510.
Results regarding the associations of these genes with asthma
are available from the European Gabriel consortium (http://www.
cng.fr/gabriel/results.html), the largest GWAS of asthma con-
ducted to date on more than 10,000 cases and 16,000 controls. No
robust association between SNPs in the three NOS genes and
asthma was found [26]. Further, none of the SNPs belonging to
either of the three genes was reported associated with asthma or
atopy in the Catalog of Published Genome-Wide Association
Studies (http://www.genome.gov/gwastudies). To our knowledge,
no partner of the Gabriel consortium has such complete data in
adults as those investigated in the present paper, and no genetic
study searching for associations between genetic variants belong-
ing to NOS genes and NO2–NO3 levels in EBC has been published
to date in the context of asthma or atopy. Further genetic studies
are needed to confirm our findings including a possible differential
effect of NOS variants on FeNO and EBC NO2–NO3 in subjects
with and without asthma. We did not find any significant
association between NOS1 variants and any biological phenotype.
This may be partly explained by the higher number of SNPs in
that gene than in NOS2 and NOS3, and thus the more stringent
threshold used to correct for multiple testing. However, regarding
FeNO levels, our results are consistent with recent observations in
Swedish adults [24].
In conclusion, this study identified NOS2 and NOS3 polymor-
phisms associated with higher levels of EBC NO2–NO3 and FeNO,
and evidenced a modifying effect of asthma status on the
associations between NOS3 genetic variants and FeNO levels.
Moreover, our findings highlight the critical relevance to have
access to specific phenotypes measured in the relevant biological
fluid (e.g. exhaled phenotypes). Genetic epidemiological studies of
biological phenotypes involved in the same pathway can provide
relevant information, and can contribute to disentangle the
mechanisms underlying complex diseases such as asthma.
Methods
Study design
The Epidemiological study on the Genetics and Environment of
Asthma (EGEA) combines a case-control study and a family study
of asthmatic cases (http://cesp.vjf.inserm.fr/ ˜egeanet/). The pro-
tocol and descriptive characteristics have been described elsewhere
[27,28]. Probands (asthmatic patients) were recruited from chest
clinics between 1991 and 1995 and family members of asthmatic
probands were included, either by including the proband’s parents
and siblings, or by including the proband’s spouse and children. In
Table 4. Associations between SNPs belonging to NOS2 and NOS3 with FeNO and total NO2–NO3 levels in exhaled breath
condensate in non-asthmatic subjects – Multivariate analysis.
Non-asthmatic subjects
Gene Marker
Baseline allele or
genotype versus Risk
allele or genotype
Risk allele/genotype
frequency LD D’/r
2 Estimate 95%CI
{ p-value
FeNO, ppb* (N=341)
NOS2
rs12601458 CC+CA vs AA 0.14 0.38/0.02 20.216 20.382; 20.050 0.01
rs6505510 AA+AC vs CC 0.40 0.097 0.034; 0.159 0.003
FeNO, ppb* (N=311)
NOS3 rs2853796 G vs T 0.48 0.056 0.024; 0.088 0.0007
EBC NO2-NO3, mmol/mg{ (N=490)
NOS2 rs4795067 AA vs AG+GG 0.35 0.09/0.002 0.137 0.051; 0.223 0.002
rs4796190 TT vs TC+CC 0.33 0.103 0.020; 0.186 0.015
*Adjusted for age, sex, height, smoking, centre and principal components.
{Adjusted for age, sex and principal components.
{95% confidence interval of regression coefficient.
doi:10.1371/journal.pone.0036672.t004
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the initial cohort was conducted between 2003 and 2007 [29]. All
subjects responded to a questionnaire based on international
standardized tools to diagnose asthma and to determine
respiratory and allergic symptoms, treatments, and environmental
exposures [28]. The present cross-sectional analysis uses data from
the follow-up in 1277 adult subjects with complete data on
eosinophils, NO-related phenotypes, current asthma and geno-
typic data (Fig. 1). Ethical approval was obtained from the relevant
institutional review board committees (Cochin Port-Royal Hospi-
tal and Necker-Enfants Malades Hospital, Paris). Written
informed consent was signed by all participants. Written informed
consent was signed by kin or guardians of the minors/children.
Phenotypes
Inclusion criteria used to define asthma in probands were based
on self-reported answers to the four questions: ‘‘Have you ever had
attacks of breathlessness at rest with wheezing?’’, ‘‘Have you ever
had asthma attacks?’’, ‘‘Was this diagnosis confirmed by a
physician?’’, and ‘‘Have you had an asthma attack in the last 12
months?’’, or a positive response to at least two questions and a
positive review of their medical record [29]. Asthma in relatives of
probands was defined as a positive answer to at least one of the
first two questions [29]. Among asthmatics, ‘‘current asthma’’ was
defined by a report of respiratory symptoms in the past 12 months
(wheeze, nocturnal chest tightness, attacks of breathlessness
following strenuous activity, at rest or at night time, and asthma
attacks) or use of inhaled and/or oral medicines because of
breathing problems. Asthmatic subjects without current asthma
were excluded from the present study. Lung function tests with
methacholine challenge, total IgE and allergy skin prick tests were
performed (see File S1).
Biological phenotypes in the nitrate-nitrite-NO pathway
Exhaled breath condensate (EBC) was collected according to a
standardized method using RTube
TM. Total nitrite-nitrate (NO2–
NO3) levels were measured by the Griess reaction [30]. Briefly,
nitrate in plasma or in EBC were reduced to nitrite by adding
nitrate reductase (25 mU/ml) and NADPH 20 mM at room
temperature and in dark. After 3 hours, samples were deprotein-
ized by adding a solution of ZNSO4 30% and centrifuged. Griess
reagent (0.1% naphthalethylene-dimine and 1% sulfanilamide in
5% H3PO4) was added to supernatants. The optical density at
560 nm was measured using a microplaque reader. Nitrate levels
were calculated by comparison with optic density 560 of standard
solutions of sodium nitrite. All measurements were done in
duplicate. Analytical intra-run imprecision (CV) of these systems
was below 3%. Measurements with coefficient of variation.15%
and extreme outliers (n=7) were excluded from the analyses.
Protein concentration in EBC was determined according to Smith
et al [31]. Total NO2–NO3 level was expressed as mM in plasma
and as mmol/mg of proteins in EBC.
FENO measurements at the 50 mL/s flow rate were realized
according to ATS/ERS recommendations [21] before other
pulmonary function tests as previously described [29]. Eosinophil
count (EOS) was obtained from white blood cell count.
Genotyping
We used all SNP data in NOS1, NOS2 and NOS3 available in the
EGEA study to maximize the SNP density. These data included
18 SNPs genotyped using Taqman Probes (Applied Biosystems,
Foster City, CA) on an ABI7900HT Sequence Detection System
as part of a previous candidate gene project and 110 SNPs
genotyped using the Illumina 610Quad array (Illumina, San
Diego, CA) as part of the Gabriel Consortium GWAS (Table S1).
The whole genotyping was performed at the Centre National de
Ge ´notypage (CNG, Evry, France). Consistency of the SNP data
with Mendelian inheritance was evaluated using the PEDCHECK
program [32]. Test of Hardy-Weinberg equilibrium was per-
formed in non-asthmatic subjects using an exact test [33]
(Table S1). After a quality control (QC) process, we selected
121 SNPs belonging to NOS1 (77 SNPs), NOS2 (37 SNPs) and
NOS3 (7 SNPs) and fulfilling the following QC criteria: call
rate$97%, minor allele frequency$5%, and Hardy-Weinberg
(HW) P-value.10
24. Pairwise linkage disequilibrium (LD) mea-
sures (r
2) between polymorphisms of each of the three NOS genes
were estimated using Haploview [34].
Statistical Methods
Analyses were conducted on the four quantitative phenotypes
under study (NO2–NO3 both in plasma and in EBC, FENO and
EOS) in subjects with and without asthma separately, because
EOS count and FENO are strongly associated with asthma, and
because of the study design. We examined the log-transformed
values of EOS and NO2–NO3, adjusted for age and sex and log-
transformed FENO adjusted for age, sex, height, smoking status
(current, ex- and non-smokers) and centre. Association between
each of these biological phenotypes and each of the 121 SNPs
(single marker analysis) was investigated by linear regression using
generalized estimated equations (GEE, MIXED procedure) to take
into account the familial dependencies [35] and adjusting for
principal components to capture population ancestry. The effect of
each SNP (on each biological phenotype) was tested under three
Figure 1. Flowchart of the studied population.
doi:10.1371/journal.pone.0036672.g001
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fitting model was selected. As FENO levels are highly influenced by
inhaled corticosteroids (ICS), association analyses in asthmatic
subjects were restricted to those who did not receive ICS in the last
three months before the FENO measurement. For each phenotype
under study, we removed outliers defined as samples beyond the
mean63 Standard Deviation units before any association analysis.
The normality of phenotype distribution was tested using the
Kolmogorov-Smirnov (K–S) test in asthmatic and non-asthmatics
separately, and only two tests were marginally significant.
To correct for the effect of testing multiple SNPs within each
gene, we estimated the effective number of independent SNPs
(Meff) using Li and Ji’s method [36], which is based on the
pairwise LD measure, r
2, between SNPs. This method has the
advantage to take into account the linkage disequilibrium (LD)
between SNPs under study, and provides an accurate approxi-
mation to the permutation based correction threshold [36]. A
Bonferroni correction was then applied using the Meff estimates
leading to p-value thresholds of 0.0015, 0.0024 and 0.01 for NOS1,
NOS2 and NOS3 respectively. We did not further correct for the
number of biological phenotypes and for the number of genes as
the four phenotypes and the three genes are not independent. For
the significant SNPs, we formally tested for heterogeneity of each
SNP effect on the phenotype between non-asthmatic and
asthmatic subjects, under the best fitting genetic model, by
introducing a SNP x asthma interaction term in the regression
model. In order to detect independent effects of SNPs belonging to
a gene, we performed stepwise regression by examining within
each gene all SNPs with a p-value less than 0.10 in single marker-
analysis and with pairwise LD r
2,0.80. All statistical analyses
were done using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
Statistical power was computed using Quanto 1.2.4 (University of
Southern California, USA, http://hydra.usc.edu/gxe).
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